Many early onset neurodevelopmental disorders are male-biased, that is they occur significantly more often in males than females. These include autism spectrum conditions (ASC; 4:1 to 9:1) (Baird et al. [@CR6]; Chakrabarti and Fombonne [@CR22]), attention-deficit hyperactivity disorder (ADHD; 3:1 to 5:1) (Szatmari et al. [@CR147]; Moffitt [@CR92]), early onset persistent antisocial behavior (10:1) (Moffitt and Caspi [@CR93]), reading disability (2:1) (Liederman et al. [@CR83]), language delay (2:1) (Salameh et al. [@CR133]; Nelson et al. [@CR102]), and Tourette's syndrome (9:2) (Wang and Kuo [@CR155]). Intrinsic biological factors are likely to explain much of the male-bias in these disorders, although sex differences in exposure to environmental risks and/or protective factors, societal expectations and values related to gender, referral biases, or biased assessments are likely contributors as well (Rutter et al. [@CR130]). Specifically, X chromosome effects and early exposure to gonadal hormones (androgens and estrogens) appear to be the most important determinants of sexual differentiation of the brain.

Two pathways to a sexually differentiated brain {#Sec1}
===============================================

First, experiments in animals clearly demonstrate that gonadal hormones produced in fetal and neonatal life act on the brain to produce sex differences in neural structure and function (De Vries and Simerly [@CR39]; Simerly [@CR138]). Gonadal hormones affect neural development by preventing programmed cell death, influencing neural connectivity, and altering neurochemical profiles (De Vries and Simerly [@CR39]). For example, gonadal hormones modulate serotonergic and γ-aminobutyric acid neurotransmission (Sumner and Fink [@CR144]; McCarthy et al. [@CR89]), promote the differentiation of vasopressin-expressing cells in the bed nucleus of the stria terminalis and medial amygdaloid nucleus (Wang et al. [@CR156]), increase cell genesis in the developing hippocampus (Zhang et al. [@CR165]), and interact with brain-derived neurotrophic factor to maintain dendritic length in the rat spinal nucleus of the bulbocavernosus (Yang et al. [@CR164]; Rasika et al. [@CR114]).

Secondly, it is now well-established that genes on the sex chromosomes are involved in sexual differentiation of the brain independent of gonadal steroid exposure. This was first suggested by studies showing sexual dimorphism in cultures of rat embryonic (E14) brain stem in the absence of sex steroids (Reisert and Pilgrim [@CR115]), and later supported by elegant studies of mice in which sex chromosomes and gonadal sex were made independent by moving the *SRY* (testis determining) gene from the Y chromosome to an autosome (De Vries et al. [@CR40]). Although most behavioral and anatomic differences were determined by the presence of ovaries or testes, some were dependent on chromosomes alone. For example, both male and female mice with XY sex chromosomes were more masculine (had a higher density of vasopressin-immunoreactive fibers) than XX mice in the lateral septum. Mice with a single X chromosome (39,X) can also be generated (Davies et al. [@CR37]) and show altered cognition in specific domains such as fear reactivity and visuospatial attention (Davies and Wilkinson [@CR36]).

However, it may not be appropriate to directly extrapolate the results of studies in rodents to humans. Two examples will demonstrate this difficulty. (1) In rodents, prenatal/neonatal testosterone produces many of its masculinizing effects after being aromatized to estrogen at the site of action. Masculinizing effects are thus, primarily, estrogen-receptor mediated. This is supported by experiments using mice in which estrogen agonists mimic testosterone effects on the sexual differentiation of behavior and experiments in which aromatase inhibitors and anti-estrogens inhibit masculinization of behavior (Mccarthy [@CR88]). In contrast, studies in the rhesus macaque suggest that the aromatization pathway is relatively unimportant in primates---estrogen agonists have limited masculinizing effects whereas the administration of a non-aromatizable testosterone, dihydrotestosterone, exerts similar effects to aromatizable testosterone (see Thornton et al. [@CR150] for review). It is generally accepted that gonadal steroid-mediated sexual differentiation of the brain in humans relies primarily on the androgen rather than the estrogen receptor. This is supported by studies showing that 46,XY humans lacking a functioning androgen receptor (complete androgen insensitivity syndrome) exhibit feminine behavior (Hines [@CR59]) while 46,XY humans with a dysfunctional aromatase enzyme or those lacking a functioning estrogen receptor exhibit masculine behavior (Grumbach and Auchus [@CR51]). (2) 45,X mice show no prenatal lethality, appear anatomically normal, and are fertile (Ashworth et al. [@CR5]). The phenotype in 45,X humans is markedly different. Only 1% of human conceptuses with X monosomy survive to birth, and those that do exhibit a complex phenotype including short stature, gonadal failure, and other problems. During evolution, a pseudoautosomal region (PAR) on the short arm of the ancestral X chromosome has been retained in humans while most of its genes have been lost or moved to autosomes in rodents (Ross et al. [@CR124]), contributing to the different phenotypes in mice and humans with 45,X karyotypes. This review will focus on the opportunities and challenges associated with studying brain development and neurodevelopmental disorders in individuals with loss of a sex chromosome.

What is Turner syndrome? {#Sec2}
========================

TS results from the complete loss of a sex chromosome (45,X) or partial loss of the X chromosome that includes the distal tip of its short arm. TS occurs in approximately 1 in 1,900 live female births, making it one of the most common human chromosomal abnormalities (Nielsen and Wohlert [@CR103]; Jacobs et al. [@CR63]). Most individuals with TS have short stature and gonadal dysfunction, and are at increased risk for other problems such as structural cardiac and renal defects, autoimmune disease, and learning disabilities. There is a broad phenotype in TS, some of which is explained by mosaicism. Mosaic individuals possess a 45,X cell line and one or more additional cell lines. Most commonly the additional cell line contains one normal X and one structurally abnormal X or Y chromosome, but it may be a normal 46,XX or 46,XY cell line (Savendahl and Davenport [@CR135]). Loss of ovarian function begins prenatally in TS, resulting in a postnatal developmental hormonal milieu that is estrogen and androgen deficient. Therefore, TS represents a powerful model for investigating both X chromosome and gonadal steroid effects.

For many years, research on TS has primarily focused on key medical issues, such as short stature and pubertal delay. Only recently, have families and physicians caring for these children begun to realize the major impact that neurocognitive deficits have on their overall success and happiness (Boman et al. [@CR14]; Saenger et al. [@CR131]). With this realization comes a need for a better understanding of brain structure and function in individuals with TS.

The cognitive phenotype(s) {#Sec3}
==========================

The majority of individuals with TS are of normal intelligence, but they may show an uneven pattern of cognitive strengths and weaknesses. Areas which often present difficulties include higher-order visual-spatial functions, visual memory, visuo-constructive abilities, and visual attention, arithmetical abilities, executive functioning (particularly inhibitory control, auditory attention, and planning), social interaction, understanding facial expression, and specific aspects of language (verbal fluency, complex syntactic knowledge, and articulation). There are also areas of preserved and even strengthened function including specific aspects of language (word knowledge, receptive and expressive abilities, and verbal memory) and rote memory (Rovet [@CR127]; Ross et al. [@CR25]; Christopoulos et al. [@CR24]).

Particularly relevant to the current discussion, females with TS are at an increased risk for certain neurodevelopmental disorders. In one study, autism was observed in five out of 150 individuals with TS (a rate of 3%) (Creswell and Skuse [@CR29]). Notably, this sample was recruited through a national survey of TS and excluded individuals who had been referred specifically for learning difficulties or behavioral problems (including autistic behavior). At the time this observation was published in the 1990s, the prevalence of autism in the normal female population was thought to be 1:10,000 (Lord et al. [@CR85]), but it is now estimated at 4:10,000 (Chakrabarti and Fombonne [@CR22]; Fombonne [@CR48]; Baird et al. [@CR7]), giving individuals with TS a 75-fold increased risk of autism. ADHD was observed in 24% of school-aged girls with TS which represents an 18-fold increase compared with girls in the general population (prevalence of 1.3%) (Russell et al. [@CR129]). There may also be an increased risk for schizophrenia. There are several published case reports (Kawanishi et al. [@CR68]; Roser and Kawohl [@CR118]) and TS occurs threefold more frequently in schizophrenic females than in the general female population (Prior et al. [@CR108]). However, a population-based screening study with sufficient power to detect a relative risk of \>2.4 for schizophrenia did not reveal such a relationship (Mors et al. [@CR98]). Finally, despite the fact that most individuals with TS are of average intelligence, one university center reported intellectual disability in 11% of the 500 individuals with TS followed in their clinic (Sybert and McCauley [@CR146]). This is a 14-fold increase when compared with the CDC estimated population incidence of 0.8%.

Brain phenotype(s) {#Sec4}
==================

The cognitive phenotype(s) observed in individuals with TS are assumed to reflect changes in neurobiological systems which serve multiple functional domains. The results of structural and functional neuroimaging studies in individuals with TS are consistent with this view. The most consistently reported findings are a reduction in the volume of the parietal lobe and an increase in the volume of the amygdala (Cutter et al. [@CR30]; Kesler et al. [@CR71]; Molko et al. [@CR95]). The parietal lobe is involved in mental rotation of objects, executive function, attention, and working memory, domains which are often impaired in individuals with TS. Functional imaging studies using positron emission tomography have reported reduced activation in parietal regions at rest (Elliott et al. [@CR45]), and functional magnetic resonance imaging studies have shown abnormal engagement of parietal and prefrontal areas during specific tasks in females with TS (Haberecht et al. [@CR55]; Molko et al. [@CR94]; Hart et al. [@CR56]; Kesler et al. [@CR72]; Beaton et al. [@CR9]). Diffusion tensor imaging (DTI) has also revealed reduced fractional anisotropy, often interpreted as reduced structural integrity, in the superior longitudinal fasciculus, a major fiber tract linking parietal and frontal regions and which includes the "where" pathway of visuospatial cognition. The "where" pathway appears to be more severely affected in TS than the "what" pathway which runs through the inferior longitudinal fasciculus (Holzapfel et al. [@CR60]). The amygdala has been implicated in the recognition of emotions from facial expressions, with a particular role in processing fear, in the detection of gaze direction and eye contact, and in the mediation of arousal produced by affective stimuli. In one study of females with TS, poorer performance on a task of recognizing fearful facial expressions was correlated with *increased* activation in the right amygdala. In contrast, within control females poorer performance correlated strongly with *reduced* activation of the right and left amygdala (Skuse et al. [@CR141]). Other brain regions where volume decreases in TS have been reported include occipital white matter, hippocampus, and thalamus. Volume increases have been reported in the cerebellar gray matter, orbitofrontal cortex, and superior and middle temporal lobes (Cutter et al. [@CR30]; Kesler et al. [@CR71]). An MR spectroscopy study of the temporal lobe suggests the increase is the result of a developmental failure to prune neurons (Rae et al. [@CR110]).

While TS is a clearly defined genetic syndrome, there are several different mechanisms which appear to contribute to the cognitive and brain phenotypes which have been observed. These include gonadal steroid deficiency, haploinsufficiency of genes on the X chromosome, failure to express imprinted genes (that is genes expressed from a chromosome derived from one parent and not the other), and the uncovering of X chromosome mutations (i.e., X-linked recessive inheritance). We will explore these mechanisms next.

Mechanisms: gonadal steroid effects {#Sec5}
===================================

The majority of females with TS have gonadal insufficiency (Pasquino et al. [@CR106]) and require exogenous sex steroids for induction of puberty. By observing whether sex steroid replacement therapy rescues any of the TS cognitive or brain phenotypes, the importance of sex steroids in the TS phenotype can begin to be defined. Romans et al. ([@CR117]) reported that performance on the Lafayette Pegboard (Haaland and Delaney [@CR54]), a motor planning task, was better in older girls with TS (ages 17--22 years) compared with adolescents (ages 13--16 years). They postulated that the improvement could be the result of the cumulative effects of estrogen replacement therapy. However, all study subjects were estrogen treated, so a direct cause--effect relationship could not be established.

More direct evidence for the positive effects of estrogen therapy on brain function come from a placebo-controlled, double-blind study of the effects of estrogen and/or growth hormone (GH) on final adult height in TS. Girls with TS were eligible to start the study between the ages of 5 and 11 years. They were randomly assigned to one of four treatment groups: estrogen (ethinyl estradiol, 25 ng kg^−1^ day^−1^, by mouth for girls ages 5--8 years; 50 ng kg^−1^ day^−1^ for girls ages 8--12), GH 0.1 mg/kg, three times weekly, subcutaneously, the combination of estrogen and GH, or placebo. All subjects received an oral and an injected medication/placebo. In the first study using this sample, cognition was tested on 30 placebo-treated and 24 estrogen-treated TS girls on one occasion at an average age of 8.1 ± 0.6 years after an average of 2.1 ± 0.9 years (range, 0.5--3 years) in the study (Ross et al. [@CR120]). About half of the children were receiving GH, however, no significant interaction effects for estrogen and GH were found. Therefore, the 2 × 2 factorial design was merged into an estrogen-yes versus estrogen-no comparison. A locally recruited age-matched control group of 29 girls was also tested. As expected, performance, but not verbal, IQ was significantly higher in the controls than in either TS group. The estrogen-treated TS group performed better than the placebo-treated TS group on two tests of verbal memory (Children's Word List immediate and delayed recall (Tucker et al. [@CR151]); *p* = 0.01 and 0.04) and one test of nonverbal memory (Digit Span backwards (Wechsler [@CR159]); *p* = 0.02), although the results were not significant after adjusting for multiple comparisons. Performance on these tests was similar for the estrogen-treated TS group and the control group.

In a second study, cognitive and motor functions were tested in 23 placebo-treated and 24 estrogen-treated girls with TS at an average age of 11.9 ± 0.5 years after an average of 4.0 ± 2.1 years, and compared with 41 control girls (Ross et al. [@CR119]). Tests for general cognitive ability, motor function, and handedness, nonverbal tasks for measurement of processing speed, and behavior questionnaires were given. Performance IQ was significantly higher in the control group. The speed of performance was improved by estrogen treatment in TS subjects, although the accuracy of timed spatial tasks was not consistently changed. Estrogen was demonstrated to have a significant positive effect on nonverbal processing speed (sum of times required for motor-free visual perception test (Colarusso and Hammill [@CR26]), test of facial recognition (Benton et al. [@CR13]), Money street map (Money et al. [@CR97]), and matching familiar figures (Kagan [@CR66])) and selective aspects of speeded motor performance such as the Lafayette pegboard (Haaland and Delaney [@CR54]).

In 2002, Ross et al. ([@CR122]) compared cognitive function of adult women with TS who were receiving estrogen replacement therapy (e.g., estrogen and progesterone sequentially and oral contraceptives) or who had apparently normal ovarian function (as demonstrated by normal menstrual cycles and adult breast development) with a group of control women. The women with TS performed more poorly than controls on measures of spatial/perceptual skills (including gestalt closure (Kaufman [@CR67]) and visual object and space perception silhouettes (Warrington and James [@CR158])), visual-motor integration (including Beery visual-motor integration (Beery [@CR11]) and Rey-copy (Denman [@CR41]; Waber and Holmes [@CR153])), affect recognition (Borod et al. [@CR15]), visual memory (including Rey-immediate and delayed recall (Denman [@CR41]; Waber and Holmes [@CR153]), WMS-R (Wechsler [@CR160]), and Warrington Faces (Warrington [@CR157])), attention (TOVA (McCarney [@CR87])---% commission errors), and executive function (Rey Figure Organization (Waber and Holmes [@CR153])) despite estrogen replacement therapy or presence of normal menses. Based on these results they argued that the core cognitive phenotype in TS is mediated by direct X chromosome effects rather than sex steroid effects. However, there was not an untreated TS control group and age at initiation of sex hormone therapy, mode of therapy, and adequacy of therapy were not reported. Sex steroids can have both organizational effects (that is permanent changes to the neural substrate, usually occurring early in development) and activational effects (transient changes, usually occurring later in life). Until recently, initiation of estrogen therapy was often delayed until age 15 years or later in an effort to maximize height. If the women in this study did not receive early estrogen replacement, the study cannot rule out a role for organizational effects of estrogen in early puberty or childhood. In addition, the predominant estrogen "replacement therapy" in the USA has been conjugated equine estrogens, which contains many estrogens, some of which are not normally found in humans. It remains to be determined if the positive effects of estrogen reported for the children in the above studies or in children who receive more physiologic estrogen replacement therapies will impact cognitive and motor function in adulthood.

Girls with TS have often been treated with oxandrolone, a non-aromatizable androgen, to accelerate linear growth. Ross et al. ([@CR123]) randomized TS girls, ages 10--14, to receive oxandrolone or placebo for 2 years. Four cognitive domains were evaluated (verbal abilities, spatial cognition, executive function, and working memory) at baseline, 1, and 2 years of the study. Three of the four domains studied did not differ between the groups. However, verbal working memory was better in the oxandrolone-treated group. A similar result was observed in a randomized, double-blind, placebo-controlled study of oral methyl testosterone treatment for 1 year in TS women between 17 and 27 years of age. Methyl testosterone improved verbal memory as well as attention and reaction time, but did not affect spatial cognition or executive function (Zuckerman-Levin et al. [@CR168]). Oxandrolone has also been reported to reduce problem behavior (as measured by the Child Behavior Checklist (Achenbach [@CR1])) in girls in which mean age at initiation was 10 years and mean age at discontinuation was 15 years (Menke et al. [@CR91]).

Absent from the current research literature are studies on the possible effects of prepubertal gonadal steroid deficiency in girls with TS. Little definitive data on sex steroid regulation in prepubertal children has been established due to the absence of sensitive, commercially available assays. Klein et al. ([@CR76]), using a highly sensitive bioassay, were the first to determine that estrogen levels in prepubertal girls are significantly higher than those of prepubertal boys. Recently, however, sensitive, very specific, and highly reproducible assays for estradiol and other sex steroids using gas chromatography combined with mass spectrometry or liquid chromatography tandem mass spectrometry (LC-MS/MS) methodologies have become commercially available. These assays are currently considered the gold standard for sex steroid measurements (Albrecht and Styne [@CR3]; Rahhal et al. [@CR111]).

Recently, LC-MS/MS was used to compare multiple sex steroids, including estradiol, in the serum of prepubertal boys and girls ages 6--11.5 years. 17-β estradiol levels in prepubertal boys were undetectable or extremely low (median, ≤3.7 pmol/l), whereas levels in prepubertal girls were significantly higher (median, 9.6 pmol/l) (Courant et al. [@CR27]). While estrogen levels have not been directly measured in young girls with TS, one would expect the majority to be estrogen deficient because of early, accelerated follicular degeneration, an assumption which is supported by markedly elevated FSH levels in most young girls with TS (Fechner et al. [@CR46]).

Also lacking in the research literature are MRI studies directly investigating the role of estrogen or androgen on the brain in TS. Only one study has addressed effects of androgen supplementation on the brain. Cutter et al. ([@CR30]) reported no differences in brain structure between 12 women who received oxandrolone and 15 who did not, using a voxel-based morphometry method. No MRI studies have assessed estrogen effects on the brain in TS. Assessing estrogen effects on the brain is complicated by the multitude of estrogen replacement regimens, including the form of estrogen, mode of delivery, timing of initiation, timing of dose acceleration, and addition of progestational agents. Finally, no studies have assessed the impact of sex steroid hormone replacement on psychiatric diagnosis or severity of symptoms in those subgroups of TS females diagnosed with ASC, intellectual disability (ID), ADHD, or schizophrenia. It is of particular interest to note that three randomized double-blind placebo-controlled trials and one open-label study have shown that giving estradiol in addition to traditional antipsychotic medications is associated with significant reduction of symptoms in women with schizophrenia (Kulkarni [@CR78]). Thus, it is plausible that estrogen deficiency could increase the risk for schizophrenia in women with TS. One of the most marked sex differences in the general population of individuals with schizophrenia is a later age of onset in females than in males, and it has been hypothesized that this is the result of the protective actions of estrogen. If this is the case, risk for schizophrenia within the TS population could vary with age at initiation of estrogen therapy.

Mechanisms: haploinsufficiency of X chromosome genes {#Sec6}
====================================================

Although typical females have two X chromosomes, only one of these is generally active. X chromosome inactivation (the process by which one X is suppressed while the other remains active) acts to negate the "dosage" difference in X chromosome genes between males and females. However, some genes on the human X chromosome continue to be expressed from the "inactive" X. It has been estimated that 15--20% of genes are expressed from the inactive X (Craig et al. [@CR28]; Carrel and Willard [@CR20]), although a recent gene expression study suggested that only 5% of X-linked genes actually achieve significantly higher expression levels in females compared with males (Johnston et al. [@CR65]). For the subset of X chromosome genes that escape inactivation, females with TS will be haploinsufficient and this may contribute to the cognitive phenotype and risk for other neurodevelopmental disorders. One approach to identify the particular genes involved is to compare phenotypes of individuals missing various portions of one sex chromosome, a strategy known as deletion mapping. Ross et al. ([@CR121]) and Zinn et al. ([@CR166]) used this approach. For their phenotype of interest, they developed a "Turner Syndrome Cognitive Summary Score" or TSCS, which was based on discriminant function analysis of a wide range of cognitive tests. While working memory, attention-impulse control, and executive function tests are included, the final score is heavily weighted towards visuospatial abilities. Results from their initial study, which included both children and adults and used TSCS score as a binary variable, suggested that Xp22.3 contains one or more genes that influence TSCS (Ross et al. [@CR121]). A subsequent study which focused only on adults and used TSCS as a quantitative variable confirmed that deletion of Xp22.3 was sufficient to cause this neurocognitive phenotype (Zinn et al. [@CR166]). This region contains 31 annotated genes and the authors highlighted two genes, *STS* and *NLGN4X* as potential candidates. *STS* has been implicated in GABA~A~ receptor function (Majewska [@CR86]) and visuospatial attention in a mouse model of TS (Davies et al. [@CR38]) and has also been linked to ADHD in humans (Doherty et al. [@CR43]; Kent et al. [@CR69]; Brookes et al. [@CR16]). *NLGN4X* mutations have been associated with ASC and X-linked ID (Chakrabarti et al. [@CR23]; Daoud et al. [@CR31]; Jamain et al. [@CR64]; Laumonnier et al. [@CR80]; Lawson-Yuen et al. [@CR81]; Talebizadeh et al. [@CR149]; Yan et al. [@CR163]; Qi et al. [@CR109]). However, it should be noted that the smallest deletion associated with the neurocognitive phenotype did not include either of these genes, but only *PLCXD1, GTPBP6, PPP2R3B,* and *SHOX*, none of which have been previously implicated in cognition or risk for neurodevelopmental disorders.

A similar strategy was applied by Good et al. ([@CR50]) to explore the cause of decreased recognition of fear in females with TS. A genetic locus (no greater than 4.96 Mb in size) was identified at Xp11.3 that affected fear recognition and amygdala volume. The authors hypothesized that the genes for monoamine oxidase A (*MAOA*) and B (*MAOB*), which are located in this region and are involved in the oxidative deamination of several neurotransmitters, including dopamine and serotonin, could be responsible for the phenotype. Subsequently, this group used regression-based association mapping to identify potential candidate genes within this region. They reported a single-nucleotide polymorphism in *EFHC2* which explained over 13% of the variation in fear recognition within women with TS (Weiss et al. [@CR161]). However, a later study by a separate lab failed to replicate this finding (Zinn et al. [@CR167]).

In conclusion, haploinsufficiency of X chromosome genes is likely to play a role in the cognitive phenotype of TS. While several interesting candidate genes have been proposed, no genes have been conclusively identified as responsible for any aspect of the cognitive phenotype.

Mechanisms: failure to express parentally imprinted genes {#Sec7}
=========================================================

Genomic imprinting refers to a process by which genetic effects are influenced according the whether the genes are transmitted through the father or the mother (Skuse [@CR139]). Ordinarily this would not result in sex differences, but it will do so if the imprinting affects the X chromosome. This possibility has been most extensively studied in relation to social and communicative impairment in TS. In 1997, Skuse et al. reported that social difficulties were more pronounced in females with TS who inherited a maternal X chromosome than in those who inherited a paternal X chromosome. Typical females inherit an X chromosome from both parents (X^p^X^m^), and typical males inherit only a maternal X (X^m^Y). The authors hypothesized that a gene expressed on the paternal X enhances social cognition and is a protective factor against ASC (Skuse et al. [@CR140]). Shortly afterwards, Creswell and Skuse reported five cases of autism from an unselected sample of 150 subjects with TS (Creswell and Skuse [@CR29]). All the affected cases were X^m^ or had a structurally abnormal paternal X. While this was certainly an exciting finding, it should be kept in mind that 77% of TS females are X^m^, while only 23% are X^p^, meaning that by chance alone one would expect to find autism in association with X^m^ more often than with X^p^. In addition, all of the autism cases in that report had low verbal IQ scores, despite the fact that intelligence is usually in the average range in TS, raising the possibility that the autism was secondary to ID. The male-to-female sex ratio for ASC is only 2:1 in individuals with moderate to severe ID in contrast to 5.5:1 in individuals with average intelligence (Fombonne [@CR48]). It is also notable that some of the autism cases had a structurally abnormal paternal X. TS individuals with small ring X chromosomes often have a severe phenotype that is not typical of TS and includes intellectual disability. In these individuals, the loss of the XIST gene, which is involved in causing X inactivation, may allow for normally inactivated genes to be expressed, resulting in functional disomy (Kubota et al. [@CR77]). Finally, Henn and Zhang ([@CR58]) raised the possibility that the presence of residual Y chromosome sequences in a subset of cells in the brain could explain the greater vulnerability of X^m^ TS females to social dysfunction, but this hypothesis is untestable without access to brain tissue.

Despite many uncertainties, the role of parentally imprinted genes in TS and in sex-biased neurodevelopmental disorders is an extremely exciting avenue for future research. Imprinting effects are now routinely tested for in MRI studies in individuals with TS and have been observed for the superior temporal gyrus (Kesler et al. [@CR70]), occipital white matter, cerebellar gray matter (Brown et al. [@CR17]), hippocampus, thalamus, and caudate (Cutter et al. [@CR30]). Imprinting effects have also been reported for non-behavioral aspects of the TS phenotype, including body mass index, lipid levels, kidney malformations, and ocular abnormalities (Sagi et al. [@CR132]).

Mechanisms: X-linked recessive inheritance and functional disomy {#Sec8}
================================================================

Like typical males, females with TS are at an increased risk of X-linked recessive conditions, including ID, as a second X is not present to balance the effects of the abnormal gene. In the general population, more than 10% of cases of ID show an X-linked pattern of inheritance, involving mutations in over 90 different genes. On the flip side, the subgroup of individuals with TS at highest risk for ID are those with small ring Xs that fail to undergo inactivation, resulting in functional disomy for normally inactivated genes (Kubota et al. [@CR77]). Intriguingly, some X-linked recessive conditions may result in the loss of the diseased X during mitosis, producing mosaic TS. This has recently been reported for female embryos carrying the full fragile X mutation (Dobkin et al. [@CR42]).

Future directions: deeper into the brain {#Sec9}
========================================

While neuroimaging has and will continue to advance our understanding of neurodevelopment in individuals with TS, current techniques are not capable of identifying the neurodevelopmental processes which underlie observed changes in tissue volumes or DTI parameters. Structural and molecular biology techniques applied to post-mortem brains complement neuroimaging approaches by identifying alterations in the number or volume of different cell types and alterations of pathway-related genes and proteins (Schmitt et al. [@CR136]). Unfortunately, post-mortem studies in individuals with TS are extremely scarce and date back several decades. Based on the limited studies available, there appears to be overall decreased cortical organization, possibly due to neuronal migration deficits (Molland and Purcell [@CR96]; Gullotta and Rehder [@CR52]; Urich [@CR152]; Reskenielsen et al. [@CR116]). Significantly, more information could be gained from post-mortem samples given technical advances and the development of more targeted hypotheses. For example, the frequency of cell line mosaicism and differences in gene expression within specific regions of the brain could be determined. Comparison to post-mortem findings in other neurodevelopmental conditions could clarify whether there is true etiological homology between conditions or if very different mechanisms produce similar behavioral outcomes. Brain banks play an important role in psychiatric research, particularly in the schizophrenia field, and it worth considering whether this strategy can be applied in the study of TS.

Future directions: deeper into the genome {#Sec10}
=========================================

One of the most striking features of the TS population is the extreme variability in phenotype. We have already discussed some genetic aspects of TS that may help explain this variability, including parental origin of X chromosome, cell line mosaicism, imprinting, and the uncovering of X-linked mutations. Variability could also result from the genetic background in which loss of the second sex chromosome occurs. Applying genome-wide analysis approaches to individuals with TS and comparing those with or without comorbid neurodevelopmental disorders could be a powerful strategy for identifying genetic risk factors on the autosomes, although limited sample sizes would be a definite issue. An alternative approach would be to select candidate genes which have emerged from genome-wide studies of relevant neurodevelopmental disorders and investigate these intensively within TS samples. For example, mutations in genes coding for synaptic cell adhesion molecules and their related proteins, such as neurexin-1 (*NRXN1*) and contactin-associated protein-like 2 (*CNTNAP2*), have been reported in association with ASC (Feng et al. [@CR47]; Szatmari et al. [@CR148]; Kim et al. [@CR73]; Bakkaloglu et al. [@CR8]; Rossi et al. [@CR126]), schizophrenia (Kirov et al. [@CR74]; Walsh et al. [@CR154]; Rujescu et al. [@CR128]; Stone et al. [@CR143]; Kirov et al. [@CR75]; Need et al. [@CR101]; Friedman et al. [@CR49]), ADHD (Elia et al. [@CR44]), and ID (Friedman et al. [@CR49]; Zweier et al. [@CR169]). Genetic and epigenetic changes on the remaining X could also contribute to phenotypic variability, with some individuals capable of compensating for the lost alleles by upregulating the remaining ones. X chromosome genes including *NLGN4*, *NLGN3*, *MECP2*, and *PTCHD1* have been linked to ASC (Daoud et al. [@CR31]; Jamain et al. [@CR64]; Laumonnier et al. [@CR80]; Lawson-Yuen et al. [@CR81]; Talebizadeh et al. [@CR149]; Yan et al. [@CR163]; Pinto et al. [@CR107]; Noor et al. [@CR104]; Shinawi et al. [@CR137]; Carney et al. [@CR19]; Lam et al. [@CR79]) and would be worthy of detailed investigation in TS. Intriguingly, post-synaptic neuroligins (which include *NLGN4* and *NLGN3*) interact with the presynaptic neurexins (such as *NRXN1*) to form trans-synaptic associations. Both groups are required for the maturation of glutamatergic excitatory and GABAergic inhibitory synapses (Leone et al. [@CR82]). We have already stated the potential value of post-mortem gene expression studies in brain, but similar approaches in more accessible tissues would also be of interest.

Future directions: going earlier in development {#Sec11}
===============================================

The majority of neuroimaging and behavioral studies of TS carried out to date have focused on older children and adults. Thus, they cannot address when in development the reported differences emerge. A better knowledge of when brain development is altered could help pinpoint the cause of functional changes and identify critical periods for intervention. In addition, older children and adults have often been exposed to many years of therapies such as GH and estrogen that are likely to impact neurodevelopment. Treatment may have produced some of the observed neural differences or it may have minimized or eliminated neural differences present before treatment began. It is now recommended that GH therapy (used to improve or normalize height) be considered as soon as growth failure is demonstrated. In the recent *"Toddler Turner Study"* study, girls ages 9 months to 4 years with TS (mean age = 2 years) were randomized to GH therapy or no therapy. Girls in the GH group achieved a height 1.6 SD above that of the no therapy group after 2 years, and averaged just 0.3 SD below the mean height for girls in the general population (Davenport et al. [@CR34]). Since growth failure typically begins in infancy, many girls with TS are now being treated with GH beginning in the first 2 years of life. However, the effect of GH on brain development in young children is unknown. Estrogen therapy is now delayed until the time of normal puberty and the effect of estrogen on brain development in the first few years of life is unknown. Studies of brain development in TS, prior to long-term hormonal therapy, will be critical in determining the potential role of standard hormone therapies in ameliorating or producing the brain changes observed in older females with TS. This information will have important implications for determining appropriate timing, type, and dosage of hormone therapies.

At present, the only neurocognitive and psychosocial data for this group comes from the Lilly "Toddler Turner Study" in which young girls with TS were followed at 4 months intervals for 2 years. At baseline, 1, and 2 years neurocognitive and psychosocial studies were performed. On the Mullen Scale of Early Learning (Mullen [@CR100]), this TS population was significantly below the normative means for the five subtests (Fine-Motor, Gross Motor, Receptive Language, Expressive Language, and Visual Reception), with approximately 20% of the sample being more than 2SDs below the mean on the overall score. On a measure of social-behavioral functioning, the Vineland Social-Emotional Early Scales (Sparrow and Balla [@CR142]), the TS group fell largely at the lower end of the average range of functioning, with the scores for Interpersonal Relationships, Play and Leisure, and the Composite being significantly below the normative means. On the Carey Temperament Scale (Carey and McDevitt [@CR18]), the girls with TS were described as less persistent, more cautious in their approach to new situations, and slower to adapt to these situations (Hooper et al. [@CR61]). The same study provides preliminary evidence that the trajectory of brain development in girls with TS from birth to 2 years of age may be considerably different that those of typical females. They compared historical birth length, weight and head circumference (HC) values corrected for gestational age \<37 weeks to those measured at study entry. While mean length and weight fell markedly from birth to study entry (∼1 SD), mean HC was relatively smaller at birth (−1.0 ± 1.2 SD) and normalized by study entry (−0.0 ± 1.2 SD), suggesting accelerated brain growth in early life (Davenport et al. [@CR33]). Interestingly, an accelerated increase in HC in the first year of life has also been reported for children with autism (Hazlett et al. [@CR57]).

Future directions: addressing the role of clinical experience and treatment on neurodevelopmental outcome {#Sec12}
=========================================================================================================

The effects of X chromosome monosomy is not restricted to the brain, but impacts almost every organ system in the body. Therefore, individuals with TS may be exposed to a wide range of medical issues and treatment paradigms which could potentially affect neurodevelopment. Despite this reality, it is unusual for published studies of cognition, behavior, or neuroimaging in individuals with TS to include detailed information on the medical history of the participants. In this review, we will highlight four common medical issues in this population and how they might impact brain development. These include growth failure (and subsequent treatment with GH), cardiovascular malformations (and related surgeries), thyroid autoimmunity, and hearing issues.

Short stature is the most common physical finding in TS, with untreated individuals achieving an average adult stature of 20 cm (8 in.) shorter than would be predicted based on parental height (Ranke and Grauer [@CR112]). Growth failure results from haploinsufficiency of the short-stature homeobox-containing gene which belongs to a family of homeobox genes, critical transcriptional regulators of early development (Rao et al. [@CR113]). Psychosocial functioning in girls with TS does not appear to be strongly related to stature, despite concerns that short stature may result in stigmatization, juvenilization, and decreased quality of life (QOL) (Sandberg and Voss [@CR134]). The standard treatment for growth failure is the administration of supraphysiological doses of GH (Davenport [@CR32]) However, the reported impact of GH on QOL has been relatively unimpressive. For example, Amundson et al. ([@CR4]) recently reported that in a group of 111 adults with TS, previous GH treatment was associated with less pain but did not mitigate the increased social isolation of this group. GH could have a direct effect on brain development, especially in younger children. Information regarding the impact of circulating GH levels and of GH supplementation in particular on human structural brain development is extremely limited, but a direct effect of circulating GH on brain structure is possible, given that GH is found in the brain and CSF and GH receptors are located in multiple brain regions including the choroid plexus, hippocampus, hypothalamus, amygdala, and pituitary (Nyberg [@CR105]). Circulating GH does not passively diffuse across the blood--brain barrier (BBB), but it may be transported across the BBB via a receptor-mediated mechanism (Coculescu [@CR25]). GH may also exert effects on brain development via insulin-like growth factor 1 (IGF-1), which appears to be actively transported across the BBB (Gunnell et al. [@CR53]). IGF-1 receptors are also present in the brain with the greatest density of receptors localized to the cortex and hippocampus (Adem et al. [@CR2]). Rodent studies demonstrate that IGF-1 plays a crucial role in neurogenesis, myelination, synaptogenesis, and dendritic branching. Transgenic mice which overexpress IGF-1 have increased brain size, while those with IGF-1 deletions have reduced brain size (Carson et al. [@CR21]; Beck et al. [@CR10]). Thus far only one structural MRI study in TS has addressed this issue. Cutter et al. ([@CR30]) reported that adult women with TS who did not use GH had significantly decreased gray matter volume bilaterally in the parieto-occipital and posterior temporal lobes and basal ganglia, compared with those who did not take GH.

Cardiovascular malformations are common in individuals with TS. In an echocardiographic study of 200 individuals, aortic coarctation with or without a bicuspid valve was present in 14%, bicuspid valve alone in 10%, aortic stenosis and/or regurgitation in 5%, and other structural defects such as hypoplastic left heart, atrial septal defect, and ventricular septal defect in 10% (Sybert [@CR145]). Such malformations represent an independent risk factor for altered brain development. Newborns with congenital heart disease (CHD) show a high frequency of acquired white matter injury. Significant problems pertaining to intelligence, neuropsychological development, and social cognition (Bellinger [@CR12]) have been documented for many children with CHD who have undergone surgery. Neurobehavioral and neurological abnormalities are also common in children with CHD prior to surgery (McQuillen and Miller [@CR90]) and may result from the same developmental event(s) that caused the cardiac defect or from damage incurred prenatally from altered blood flow or oxygenation. For example, coarctation/aortic arch hypoplasia increases the risk for microcephaly at birth 2.8-fold.

Individuals with TS are at increased risk for autoimmune disorders and the risk increases with age (Mortensen et al. [@CR99]). Thyroiditis is the most common autoimmune disorder and has been reported as early as 4 years of age. In a study of 84 children with TS who were followed longitudinally for an average of 8 years, 20 developed hypothyroidism and two developed hyperthyroidism (Livadas et al. [@CR84]). Hypothyroidism has profound effects on neurodevelopment and may have more subtle effects when present subclinically or transiently (Williams [@CR162]).

Sixty to 80% of individuals with TS suffer from conductive hearing loss because of chronic otitis media (Hultcrantz [@CR62]). This may be related to having a short, horizontally oriented eustachian tube which results in poor drainage and ventilation of the middle ear space. Ear infections are especially common in the first few years of life. For example, in the "Toddler Turner Study", at the baseline study visit (mean age = 2 years), 26% had tympanostomy tubes present, another 64% had evidence of abnormal middle ear function, and 27% had abnormal hearing in one or both ears (Davenport et al. [@CR35]). In addition, progressive sensorineural hearing loss with a unique dip in the 1.5--2 kHz region and/or a high frequency loss (above 8 kHz) may present very early and necessitate the use of hearing aids in childhood. Early hearing difficulties could clearly impact the development of language and socialization and should be documented in research studies as well as dealt with quickly in the clinic.

Conclusions {#Sec13}
===========

Turner syndrome is one of the most common sex chromosome abnormalities and as such represents an important health problem. In addition, studies carried out in this population can help us model the effects of both sex hormones and genes on the X chromosome in early brain development and thereby better our understanding of the differential vulnerability to and expression of neurodevelopmental disorders in males and females. This research paradigm has already produced novel theories, such as the X-linked parental imprinting theory of autism. However, disentangling the contribution of steroid hormones and genetic factors is challenging. We suggest several directions for future research to help resolve these issues including carrying out neuroimaging studies at earlier time-points, pursuing post-mortem studies with the latest structural and molecular biology techniques, applying modern genomics strategies, and the routine consideration and reporting of medical history.
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